<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab, which is a humanized monoclonal antibody against vascular endothelial growth factor, is used to treat <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancers</z:e> of the colon </plain></SENT>
<SENT sid="1" pm="."><plain>Adverse effects common with bevacizumab treatment are <z:hpo ids='HP_0000822'>hypertension</z:hpo>, arterial-<z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp>, gastrointestinal <z:mpath ids='MPATH_81'>perforation</z:mpath>, and <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To date, there have been no reports of refractory <z:hpo ids='HP_0001250'>seizure</z:hpo> following treatment with bevacizumab </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a patient who presented with refractory <z:hpo ids='HP_0002069'>generalized tonic-clonic seizures</z:hpo> after receiving last dose of bevacizumab for treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> with FOLFIRI and bevacizumab regimen </plain></SENT>
</text></document>